Infectious complications of biological and small molecule targeted immunomodulatory therapies

JS Davis, D Ferreira, E Paige, C Gedye… - Clinical microbiology …, 2020 - Am Soc Microbiol
The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Antibody-independent functions of B cells during viral infections

V Upasani, I Rodenhuis-Zybert, T Cantaert - PLoS pathogens, 2021 - journals.plos.org
The humoral immune response and antibody-mediated functions of B cells during viral
infections are well described. However, we have limited understanding of antibody …

[HTML][HTML] Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency …

IM Otani, HK Lehman, AM Jongco, LR Tsao… - Journal of Allergy and …, 2022 - Elsevier
Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind …

K Iijima, M Sako, K Nozu, R Mori, N Tuchida, K Kamei… - The Lancet, 2014 - thelancet.com
Background Rituximab could be an effective treatment for childhood-onset, complicated,
frequently relapsing nephrotic syndrome (FRNS) and steroid-dependent nephrotic …

Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study

C Hsu, HH Tsou, SJ Lin, MC Wang, M Yao… - …, 2014 - Wiley Online Library
Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection
(hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti‐HBc] …

[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …

M Mikulska, S Lanini, C Gudiol, L Drgona… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic

RA Kessler, MA Mealy, M Levy - Current treatment options in neurology, 2016 - Springer
Opinion statement Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune
disease of the central nervous system that primarily attacks the optic nerves and spinal cord …

Serologic vaccination response after solid organ transplantation: a systematic review

I Eckerle, KD Rosenberger, M Zwahlen, T Junghanss - PloS one, 2013 - journals.plos.org
Background Infectious diseases after solid organ transplantation (SOT) are one of the major
complications in transplantation medicine. Vaccination-based prevention is desirable, but …

Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab

EAA Christou, G Giardino, A Worth… - … Reviews of Immunology, 2017 - Taylor & Francis
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of
hematological malignancies and autoimmune diseases. The use of RTX is related to the …

Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes

M Makatsori, S Kiani-Alikhan, AL Manson… - … Journal of Medicine, 2014 - academic.oup.com
Background: Rituximab, a chimeric monoclonal antibody against CD20, is increasingly used
in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B …